Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | CCR1 | P32246 | 4/20 | 0.58 |
| ▸ | CCR8 | P51685 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | HTT | P42858 | 4/20 | 0.58 |
| ▸ | CCR5 | P51681 | 3/20 | 0.58 |
| ▸ | MMP2 | P08253 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.58 |
| ▸ | GMNN | O75496 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8404537 | 0.79 | LMNA (0.68) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL4473876 | 0.78 | LMNA (1.00) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL12932576 | 0.77 | CCR1 (0.58) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL623096 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL22026143 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL23954442 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL5546382 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL10911576 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL17962397 | 0.76 | LMNA (0.63) | LMNACCR1CCR8KDM4EMAPT | |
| SCHEMBL4538171 | 0.76 | LMNA (0.58) | LMNACCR1CCR8KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| CN-115572258-A | C 2 Preparation method of axial chiral biquinoline framework compound | 中国科学院成都有机化学有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2022-09-22 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-4010328-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | Domain Therapeutics (FR) | 2022-06-15 | — | — | EP | disclosed |
| CN-114269730-A | 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists | 多曼治疗学公司 | 2022-04-01 | — | — | CN | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-111233859-B | Organic compound, organic electroluminescent material and application thereof | 武汉天马微电子有限公司 | 2021-11-19 | — | — | CN | disclosed |
| WO-2021023813-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-02-11 | — | — | WO | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
| CN-1980930-B | 8- [ 3-amino-piperidin-1-yl ] -xanthines, their preparation and their use in the form of DPP-IV inhibitors | BOEHRINGER INGELHEIM INT | 2012-11-21 | — | — | CN | disclosed |
| CN-102199151-A | 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use | BOEHRINGER INGELHEIM INT | 2011-09-28 | — | — | CN | disclosed |
| US-20110014121-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-2119717-A1 | 8-[3-amino-piperidin-1-yl]-xanthins, their production and utilisation as DPP IV inhibitors | Boehringer Ingelheim International GmbH (DE) | 2009-11-18 | — | — | EP | disclosed |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-1758905-B1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | BOEHRINGER INGELHEIM INT (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-7501426-B2 | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-10 | — | — | US | disclosed |
| CN-1980930-A | 8- [ 3-amino-piperidin-1-yl ] -xanthines, their preparation and their use in the form of DPP-IV inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1758905-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DDP-IV INHIBITOR | Boehringer Ingelheim International GmbH (DE) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005085246-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINE, THE PRODUCTION THEREOF AND THE USE IN THE FORM OF A DPP INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014121-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | LMNA 4842/4885CCR1 19/4885CCR8 16/4885 |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | LMNA 2478/4885CCR1 551/4885CCR8 1036/4885 |
| US-20090137801-A1 | 8-[3-AMINO-PIPERIDIN-1-YL]-XANTHINES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP8, DPP4, DPP7 | LMNA 2911/4885CCR1 807/4885CCR8 165/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | LMNA 2478/4885CCR1 551/4885CCR8 1036/4885 |
| US-20220298135-A1 | 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS | NPFFR2, NPFFR1, OPRL1 | LMNA 4712/4885CCR1 2083/4885CCR8 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.